BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/15/2023 6:05:28 AM | Browse: 606 | Download: 1684
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 82872
Country South Korea
ISSN 1948-5204 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Surgery
Manuscript Type Review
Article Title Role of neoadjuvant therapy for nonmetastatic pancreatic cancer: Current evidence and future perspectives
Manuscript Source Invited Manuscript
All Author List Gianluca Cassese, Ho-Seong Han, Yoo‐Seok Yoon, Jun Suh Lee, Boram Lee, Antonio Cubisino, Fabrizio Panaro and Roberto Ivan Troisi
ORCID
Author(s) ORCID Number
Gianluca Cassese http://orcid.org/0000-0001-9185-2054
Ho-Seong Han http://orcid.org/0000-0001-9659-1260
Jun Suh Lee http://orcid.org/0000-0001-9487-9826
Fabrizio Panaro http://orcid.org/0000-0001-8200-4969
Roberto Ivan Troisi http://orcid.org/0000-0001-6280-810X
Funding Agency and Grant Number
Corresponding Author Ho-Seong Han, MD, Professor, Department of Surgery, Seoul National University Colllege of Medicine, 166 Gumi-ro, Bundang-gu, Seongnam 13620, Gyeonggi-do, South Korea. hanhs@snubh.org
Key Words Pancreatic cancer; Pancreatic duct adenocarcinoma; Neoadjuvant chemotherapy; Borderline resectable; Locally advanced pancreatic cancer
Core Tip Pancreatic adenocarcinoma (PDAC) is one of the most common and lethal human cancers worldwide; yet patients diagnosed with it still have a poor prognosis. Multimodal therapy is one of the most promising treatment options that increase the overall survival. Neoadjuvant chemotherapy (NACT) is recommended for treating borderline resectable PDAC. While recent studies have tried to explore the role of NACT in treating resectable and locally advanced PDAC, novel therapeutic modalities, such as ct-DNA and molecular targeted therapy, may guide both treatment and monitoring during the disease course to improve prognosis.
Publish Date 2023-06-15 06:05
Citation Cassese G, Han HS, Yoon YS, Lee JS, Lee B, Cubisino A, Panaro F, Troisi RI. Role of neoadjuvant therapy for nonmetastatic pancreatic cancer: Current evidence and future perspectives. World J Gastrointest Oncol 2023; 15(6): 911-924
URL https://www.wjgnet.com/1948-5204/full/v15/i6/911.htm
DOI https://dx.doi.org/10.4251/wjgo.v15.i6.911
Full Article (PDF) WJGO-15-911-with-cover.pdf
Full Article (Word) WJGO-15-911.docx